FATE

+ Watchlist + Portfolio

Fate Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.65
52-Week Range: $0.93 – $3.23
Market Cap: $293.56M
P/E (TTM): —
EPS (TTM): -1.05
Dividend Yield: —

Advanced Metrics

Price/Book: 1.86
PEG Ratio: —
Return on Equity: -60.75%
Return on Assets: -26.22%
Gross Margin: 0.00%
Operating Margin: -1495.39%
Profit Margin: 0.00%
Current Ratio: 4.85
Debt/Equity: 0.49
Total Debt: $75.67M
Free Cash Flow: $-48.66M
Revenue Growth: 9.20%
Earnings Growth: —
Enterprise Value: $239.43M

FATE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$96.30M	$63.53M	$13.63M	$6.65M
Research & Development	$320.45M	$172.60M	$135.00M	$107.83M
Selling, General & Admin	$84.23M	$81.45M	$74.17M	$46.52M
Operating Expenses	$404.69M	$254.04M	$209.17M	$154.35M
Operating Income	-$308.39M	-$190.51M	-$195.54M	-$147.70M
EBITDA	-$294.63M	-$172.23M	-$176.58M	-$134.80M
Pretax Income	-$281.72M	-$160.93M	-$186.26M	-$136.31M
Net Income	-$281.72M	-$160.93M	-$186.26M	-$136.31M
Diluted EPS	-2.91	-1.64	-1.64	-1.15
Diluted Shares	96.83M	98.41M	113.69M	118.79M

FATE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$61.33M	$41.87M	$36.06M	$46.63M
Receivables	$38.48M	$1.83M	$3.54M	$916.00K
Current Assets	$502.07M	$331.54M	$291.91M	$208.70M
Total Assets	$705.56M	$506.22M	$440.69M	$318.94M
Current Liabilities	$114.05M	$39.09M	$38.52M	$36.07M
Total Debt	$109.34M	$103.54M	$85.27M	$77.85M
Total Liabilities	$221.62M	$137.80M	$121.97M	$111.75M
Retained Earnings	-$1.05B	-$1.21B	-$1.40B	-$1.53B
Shareholders' Equity	$483.94M	$368.42M	$318.73M	$207.18M
Working Capital	$388.02M	$292.45M	$253.39M	$172.63M

FATE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$248.21M	-$132.26M	-$122.87M	-$106.08M
Capital Expenditure	-$35.57M	-$6.15M	-$730.00K	-$5.95M
Free Cash Flow	-$283.77M	-$138.42M	-$123.60M	-$112.04M
Depreciation & Amortisation	$13.76M	$18.28M	$18.96M	$12.90M
Stock-Based Compensation	$78.73M	$43.46M	$41.50M	$24.92M
Investing Cash Flow	$166.75M	$112.67M	$12.22M	$111.17M
Financing Cash Flow	$9.21M	$85.00K	$99.89M	$5.49M
Net Change in Cash	-$72.25M	-$19.51M	-$10.76M	$10.57M

FATE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.63M	$1.91M	$1.74M	$1.37M	$1.30M
Research & Development	$29.14M	$27.43M	$25.84M	$25.43M	$24.70M
Selling, General & Admin	$13.77M	$11.45M	$10.64M	$10.66M	$9.60M
Operating Expenses	$42.91M	$38.88M	$36.48M	$36.09M	$34.30M
Operating Income	-$41.28M	-$36.97M	-$34.73M	-$34.72M	-$33.00M
EBITDA	-$37.95M	-$33.69M	-$31.51M	-$31.66M	-$30.08M
Pretax Income	-$37.62M	-$34.07M	-$32.25M	-$32.37M	-$31.21M
Net Income	-$37.62M	-$34.07M	-$32.25M	-$32.37M	-$31.21M
Diluted EPS	-0.32	-0.29	-0.27	-0.27	-0.26
Diluted Shares	118.38M	118.53M	119.00M	119.25M	120.03M

FATE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$44.92M	$41.25M	$40.62M	$46.63M	$39.57M
Receivables	$2.41M	$1.40M	$682.00K	$916.00K	$704.00K
Current Assets	$248.22M	$230.40M	$221.25M	$208.70M	$179.53M
Total Assets	$398.67M	$371.63M	$343.67M	$318.94M	$284.92M
Current Liabilities	$28.16M	$28.67M	$28.11M	$36.07M	$30.69M
Total Debt	$83.33M	$81.33M	$79.25M	$77.85M	$76.78M
Total Liabilities	$110.26M	$110.27M	$109.61M	$111.75M	$105.21M
Retained Earnings	-$1.44B	-$1.47B	-$1.50B	-$1.53B	-$1.57B
Shareholders' Equity	$288.41M	$261.36M	$234.07M	$207.18M	$179.71M
Working Capital	$220.06M	$201.72M	$193.14M	$172.63M	$148.84M

FATE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$33.81M	-$24.59M	-$24.37M	-$23.31M	-$30.82M
Capital Expenditure	-$1.20M	-$1.36M	-$2.20M	-$1.19M	-$239.00K
Free Cash Flow	-$35.01M	-$25.95M	-$26.58M	-$24.51M	-$31.06M
Depreciation & Amortisation	$3.33M	$3.28M	$3.23M	$3.06M	$2.92M
Stock-Based Compensation	$7.38M	$7.15M	$4.86M	$5.53M	$3.93M
Investing Cash Flow	$42.67M	$19.59M	$21.27M	$27.63M	$23.59M
Financing Cash Flow	$0.00	$1.32M	$2.48M	$1.69M	—
Net Change in Cash	$8.86M	-$3.67M	-$627.00K	$6.01M	-$7.24M

Market Snapshot

About

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs), which offer the potential for mass production and immediate availability. Fate Therapeutics has a pipeline of CAR T-cell and CAR NK-cell product candidates targeting various hematologic malignancies and solid tumors. The company's proprietary iPSC product platform is designed to overcome limitations of patient-specific cell therapies and enable more scalable manufacturing.